{
  "trial_id": "NCT00796991",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, race, ECOG performance status, histologic diagnosis, baseline tumor measurements, prior treatments, liver function tests (bilirubin, AST, ALT), presence of brain metastases, autoimmune disease history, use of immunosuppressing therapies.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Eastern Cooperative Oncology Group (ECOG)",
          "ECOG performance status"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Region of Enrollment",
        "Number of Target Lesions"
      ],
      "remaining_candidate_features": [
        "race",
        "histologic diagnosis",
        "baseline tumor measurements",
        "prior treatments",
        "liver function tests (bilirubin, AST, ALT)",
        "presence of brain metastases",
        "autoimmune disease history",
        "use of immunosuppressing therapies."
      ]
    },
    "processed-gen-response": "Age, gender, race, ECOG performance status, histologic diagnosis, baseline tumor measurements, prior treatments, liver function tests (bilirubin, AST, ALT), presence of brain metastases, autoimmune disease history, use of immunosuppressing therapies."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, Baseline Disease Characteristics, Prior Treatments, Liver Function Tests (Total Bilirubin, AST, ALT),",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Eastern Cooperative Oncology Group (ECOG)",
          "ECOG Performance Status"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Number of Target Lesions"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Baseline Disease Characteristics",
        "Prior Treatments",
        "Liver Function Tests (Total Bilirubin, AST, ALT)"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, ECOG Performance Status, Baseline Disease Characteristics, Prior Treatments, Liver Function Tests (Total Bilirubin, AST, ALT)"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Gender, Ethnicity (NIH/OMB), ECOG Performance Status, Region of Enrollment, Histologic diagnosis of advanced malignant melanoma, Measurable/evaluable disease, Total Bilirubin, AST, ALT, Prior Autoimmune disease, Use of immunosuppressing therapies.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Gender"
        ],
        [
          "Eastern Cooperative Oncology Group (ECOG)",
          "ECOG Performance Status"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Number of Target Lesions"
      ],
      "remaining_candidate_features": [
        "Ethnicity (NIH/OMB)",
        "Histologic diagnosis of advanced malignant melanoma",
        "Measurable/evaluable disease",
        "Total Bilirubin",
        "AST",
        "ALT",
        "Prior Autoimmune disease",
        "Use of immunosuppressing therapies."
      ]
    },
    "processed-gen-response": "Age, Gender, Ethnicity (NIH/OMB), ECOG Performance Status, Region of Enrollment, Histologic diagnosis of advanced malignant melanoma, Measurable/evaluable disease, Total Bilirubin, AST, ALT, Prior Autoimmune disease, Use of immunosuppressing therapies."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, weight, height, body mass index (BMI), ECOG performance status, histologic diagnosis of advanced malignant melanoma, measurable/evaluable disease as per modified World Health Organization (mWHO) criteria, total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), medical history of autoimmune disease, history of immunosuppressing therapies, prior treatment with anti-cytotoxic lymphocyte antigen 4 (CTLA-4) or anti-CD137 antibody.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Eastern Cooperative Oncology Group (ECOG)",
          "ECOG performance status"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Region of Enrollment",
        "Number of Target Lesions"
      ],
      "remaining_candidate_features": [
        "race",
        "weight",
        "height",
        "body mass index (BMI)",
        "histologic diagnosis of advanced malignant melanoma",
        "measurable/evaluable disease as per modified World Health Organization (mWHO) criteria",
        "total bilirubin",
        "aspartate aminotransferase (AST)",
        "alanine aminotransferase (ALT)",
        "medical history of autoimmune disease",
        "history of immunosuppressing therapies",
        "prior treatment with anti-cytotoxic lymphocyte antigen 4 (CTLA-4) or anti-CD137 antibody."
      ]
    },
    "processed-gen-response": "Age, sex, race, weight, height, body mass index (BMI), ECOG performance status, histologic diagnosis of advanced malignant melanoma, measurable/evaluable disease as per modified World Health Organization (mWHO) criteria, total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), medical history of autoimmune disease, history of immunosuppressing therapies, prior treatment with anti-cytotoxic lymphocyte antigen 4 (CTLA-4) or anti-CD137 antibody."
  }
}